| Name | Title | Contact Details |
|---|---|---|
Margarita Giron |
Chief Security Officer | Board Member | Profile |
A Global Development Expedition FOR women, not ABOUT women. Signature Leaders is designed to augment, rather than replace, existing corporate executive leadership development. These are programs for women with the highest potential, to fast-track them into next level leadership. These women are managing large P&Ls, leading transformations across the enterprise or sizeable functional teams, or in that critical "pivot" from managing to leading. We gather these elite leaders from around the world for introspective learning and external connections. Our executive faculty covers our framework of Who You Are, How You Show Up, and How You Relate to Others. Unlike typical seminars or conferences, participants will join the Signature community upon enrollment. This means the opportunities for learning and growth starts prior to, and continues beyond, the immersion session. Signature alumni move forward with an invaluable network of more than 2,300 peers and 250 executive faculty members and advisors who support them throughout their ongoing leadership journey. Why Signature as a name? Because every executive has a unique style and "signature" embedded in the way they lead. Our curriculum focuses on the essential capabilities needed for next level leadership in a way that encourages executives to broaden, not change their own distinct style – the leadership signature that makes them authentic.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
A company dedicated to excellence in the insurance and financial services industries. Through data-driven management and lasting relationships, IH has built a solid foundation capable of taking companies to the next level of performance, profitability, and stability. Our business approach is straightforward. We believe that the power and success behind any business or industry lie within knowledge – knowledge of your products, the direction of your company, and the ongoing execution of a stellar strategic plan. These core assets, coupled with unmatched talent from a thriving corporate culture, are what we believe to be the key ingredients for achieving profitable, steady growth.